Leal Therapeutics
PrivateLast Round
Series A
Extension
Aug 17, 2026
Total Funding Raised
$99M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Leal Therapeutics operates in Healthcare & Life Sciences and is based in Worcester, Massachusetts. Its latest recorded funding round was a Series A Extension round in August 2026.
Leal Therapeutics is a biotechnology company that develops innovative neuro-metabolic therapeutic solutions for major central nervous system conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Leal Therapeutics Comparables
Compare Leal Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SciNeuro Pharmaceuticals | 83% | |
| Tortugas Neuroscience | 81% | |
| Cerevance | 81% |
For institutional investors. Book with your work email.
Leal Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Aug 17, 2026 | ||||
| Series A | Aug 27, 2025 | ||||
| VC Round | Oct 30, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Leal Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Newpath Partners | Series A, Series A Extension, VC Round |
| SV Health Investors | Series A Extension, Series A |
| OrbiMed | Series A, Series A Extension, VC Round, Seed |
| Chugai Venture Fund | Series A, Series A Extension, VC Round |
| Alexandria Venture Investments | Series A, Series A Extension, VC Round |
| PhiFund Ventures | Series A, Seed, Series A Extension, VC Round |
| Euclidean Capital | VC Round, Series A, Seed, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 17, 2026
$30M round with participation from OrbiMed and Alexandria Venture Investments.
- Apr 13, 2026
Raymond Jordt appointed as new Chief Business Officer.
For institutional investors. Book with your work email.
Leal Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Leal Therapeutics's valuation, stock price, and market status.
Is Leal Therapeutics a public or private company?
Leal Therapeutics is a private company.
What is the current stock price of Leal Therapeutics?
Leal Therapeutics is a private company, so its shares have no public market price. Caplight tracks Leal Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Leal Therapeutics worth (valuation)?
Valuation information for Leal Therapeutics is not publicly available.
Can I buy Leal Therapeutics stock?
Leal Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Leal Therapeutics's last funding round?
Leal Therapeutics's most recent funding round was Series A Extension on August 17, 2026.
Who are the main investors in Leal Therapeutics?
Key investors in Leal Therapeutics include Newpath Partners, SV Health Investors, OrbiMed.
Will Leal Therapeutics IPO soon?
No public IPO plans have been announced for Leal Therapeutics.
How can I track Leal Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Leal Therapeutics's shares on secondary markets.